congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Disease Area Tab
PublicationView
Poster
Valemetostat
SOHO 2024 Annual Meeting | September 4-7, 2024
A phase 1 trial of valemetostat in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL)
Poster
DS-1103, T-DXd
ESMO 2023 | October 20-24, 2023
A phase 1, 2-part, multicenter, first-in-human, dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors
Poster
Other/Multi
AACR 2024 | April 5-10, 2024
A phase 1/2, first-in-human study of DS-3939a in patients with advanced solid tumors: A new DXd ADC targeting TA-MUC1
Poster
Other/Multi
ASCO 2024 | May 31 - June 4, 2024
A phase 1/2, first-in-human study of DS-3939a in patients with advanced solid tumors: A new DXd ADC targeting TA-MUC1
Poster
Dato-DXd, T-DXd, Valemetostat
ASCO 2024 | May 31 - June 4, 2024
A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody-drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors
Poster
Pexidartinib
CTOS 2023 | November 1-4, 2023
A phase 3 study of the efficacy and safety of pexidartinib in Asian patients with tenosynovial giant cell tumor
Oral
Pexidartinib
CTOS 2023 | November 1-4, 2023
A phase 4, multicenter, global clinical trial to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib
Poster
HER3-DXd
AACR 2024 | April 5-10, 2024
An evaluation of patritumab deruxtecan (HER3-DXd, U3-1402) against pediatric PDX models for hepatoblastoma and rhabdomyosarcoma – a report from the NCI PIVOT program
Poster
Dato-DXd
ASCO 2024 | May 31 - June 4, 2024
Analysis of drug-related interstitial lung disease (ILD) in patients treated with datopotamab
deruxtecan (Dato-DXd)
Poster
Quizartinib
ASH 2023 | December 9-12, 2023
CHIP-AML22 master protocol: An open-label clinical trial in newly diagnosed pediatric de novo acute myeloid leukemia patients including a linked phase II trial with quizartinib in FLT3-ITD/NPM1WT patients – a study by the NOPHO-DB-SHIP consortium